WebJun 24, 2024 · Michail Ignatiadis, a medical oncologist at the Jules Bordet Institute in Brussels, thinks that the start-up’s platform might represent an important step forward for ctDNA-based liquid biopsies. WebMay 28, 2024 · TPS597 Background: Early stage triple negative breast cancer (TNBC) is associated with a high risk of distant relapse. Because TNBC does not currently have specific targeted agents approved for use in the early setting, it is treated primarily with chemotherapy. TNBC may be more immunogenic than other subtypes of breast cancer. …
Michail Ignatiadis Jules Bordet Institute
WebPregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials — Mayo Clinic WebIgnatiadis, M. et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in ... home show wv
EORTC Breast Cancer Group Autumn Meeting - EORTC
WebElectronic address: [email protected]. 2 Department of Gynecology and Obstetrics, Ludwig-Maximilians-Universität, Munich, Germany. 3 Breast Cancer … WebMichail Ignatiadis. Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles. Verified email at bordet.be. Breast Cancer. Articles Cited by Public access Co … WebMichail Ignatiadis: 13:10-13:20: Update on the EORTC Governance: Vassilis Golfinopoulos: 13:20-14:00: General topics – EORTC BCG research agenda 2024-2024 (Michail Ignatiadis) – New format Autumn Meeting 2024 (Michail Ignatiadis) – Update from Young Investigators (J. Lopes Cardozo) hiring lvn sacramento